Acelyrin, Inc. (NASDAQ:SLRN) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET

Company Participants

Tyler Marciniak - VP of Investor Relations, Communications, and Corporate Operations

Shao-Lee Lin - Founder and Chief Executive Officer

Paul Peloso - Chief Medical Officer

Gil Labrucherie - Interim Chief Financial Officer

Conference Call Participants

Tyler Van Buren - TD Cowen

Akash Tewari - Jefferies

Vikram Purohit - Morgan Stanley

Operator

Good afternoon and welcome to the ACELYRIN, INC. Conference Call to discuss its Financial Results for the Second Quarter 2023 and Other Corporate Updates. This conference call is being recorded today, August 14, 2023.

I would now like to turn the conference call over to Tyler Marciniak, Vice President of Investor Relations, Communications, and Corporate Operations for ACELYRIN. Tyler?

Tyler Marciniak

Thank you. Good afternoon, everyone, and thank you for joining us. Before we begin, I'd like to remind the audience that this conference call will contain forward-looking statements such as those related to our development milestones, including progress of our clinical trials and anticipated data readout, our future financial and operating results and investments, the pipeline and program potential of izokibep, and our ability to commercialize our product candidates. These forward-looking statements involve risks and uncertainties that could cause our actual results and events to differ materially from those contained in such statements.

We urge you to review the Risk Factors section of our quarterly report on Form 10-Q for the quarter ended June 30 filed with the SEC and also available through the Investor Relations section of our website at acelyrin.com, along with statements contained in today's press release and our slide presentation, which identifies certain factors that could cause our actual results, performance, and events to differ materially from those contained in such forward-looking statements. Additionally, these statements are based on information available to us today, August 14, 2023, and we undertake no obligation to update them as circumstances may change.

Joining us on today's call are Dr. Shao-Lee Lin, our Founder and Chief Executive Officer; Dr. Paul Peloso, our Chief Medical Officer; and Gil Labrucherie, our Interim Chief Financial Officer.

I will now turn the call over to Dr. Lin. Shao-Lee?

Shao-Lee Lin

Thank you, Tyler, and good afternoon, everyone, and thank you for joining us for ACELYRIN's first quarterly earnings call as a public company. ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. We are driven by our sense of urgency to bring life-changing therapies to patients globally, a core value that we refer to as Courageous Caring. And our initial focus is on the treatment of immunologic diseases, an area where our team brings industry-leading expertise.